Revelation Biosciences reports Q2 2026 results, advances AKI trial prep

Revelation Biosciences, Inc. reported financial results for the three and six months ended June 30, 2026 on August 6, 2026. During the period, the company announced formation of an Acute Kidney Injury Advisory Board for the upcoming Phase 2/3 AKI clinical trial and subsequent expansion of the AKI Advisory Board, and continued progress on Phase 2/3 clinical study start up activities.¹

The company also released results of an independent market assessment that showed a potential $94 billion total addressable market for Gemini.¹ CEO James Rolke said start-up activities for the pivotal clinical study of Gemini in acute kidney injury patients continue to progress, with a focus on starting enrollment by year-end.¹

Gemini is described as the company's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist.¹ Beyond the acute kidney injury program (GEM-AKI), Gemini is also being developed as a treatment for chronic kidney disease (GEM-CKD), as a treatment to reduce hyperinflammation and infection associated with severe burn (GEM-PBI), and as a treatment to prevent post-surgical infection (GEM-PSI).¹

On the balance sheet, as of June 30, 2026, Revelation had $11.5 million in cash and cash equivalents, compared to $10.7 million as of December 31, 2025.¹ The company said the increase in cash and cash equivalents was primarily due to net cash proceeds from the January 2026 warrant inducement, offset by cash used for operating activities.¹

Revelation said based on current operating plans and projections, it believes its current cash and cash equivalents are sufficient to fund operations through the first quarter of 2027.¹